Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
What it means
- What to watch: There is a hard number in this story (15%) — the interesting part is how it compares with the last few like it.
- How the stock is trading: $MRNA +12.72% in the latest session.
- Timing: It came out pre-market, so the next session was the first that could react.
Where the stock stands
$MRNA last traded at $272.17, +12.72% on the session. That puts it -4.3% shy of its 52-week high of $261.00 and 1122% clear of its low of $22.28 — within a tenth of its 52-week high. Over the year it has ranged 1071% from low to high: a very wide band — this one has spent the year on a roller coaster, and big swings are business as usual. These are latest-session quotes, not live prices — the live tape is on the $MRNA page.
How much coverage it is getting
Wook has logged 19 stories on $MRNA in the last 30 days, 3 of them this week. At its 30-day pace you would expect about 4 a week, so this week is quieter than usual — the spotlight has wandered elsewhere for now. Across those stories the wording ran 21% bullish, 53% neutral and 26% bearish. This one reads bullish, so it sits in a small minority of the run. 3 came from CNBC and the rest from other outlets — broad coverage, not one desk talking to itself. 12 related stories from the same name or desk are listed beside this one.
The bigger picture
With earnings, the number matters less than the number versus expectations — and guidance often matters more than both. A beat paired with a soft outlook can still get a cold reception. On Wook's supply-chain scanner, Health Care reads watch today — early signs of strain worth keeping an eye on.
Coming up
$MRNA earnings today. These were on the calendar before this story and are not caused by it, but the nearest is close enough that the next hard numbers on this company are almost here.
What to watch next
For the receipts, the $MRNA page has the full chart, the filings and the valuation model these figures come from. Comparing how two or three outlets frame the same story is the fastest way to separate the facts from the angle. And Wook AI, up top, will happily do the math — how far $MRNA sits from its high, or how this week's coverage stacks up.
How this analysis was made
CNBC published it, and Wook filed it under Earnings. It reads bullish at medium severity because of “gain” and “growth” in the wording, with nothing on the bearish side to offset them. It was matched to $MRNA. It carried 15%, 25% and 10%, shown as published and not recalculated. The preview above is the publisher's own wording.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
CNBC published this on November 6, 2026. $MRNA has moved +3.66% ($262.55 to $272.17). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.